...read the wave

Nano Biz...in depth... im detail


Nanogen Expands European Distribution Network for Point-of-Care Diagnostics

SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today its subsidiary SynX signed five new European distributors for its point-of-care products. The additional distribution agreements significantly increase SynX's coverage to 28 European nations. All of SynX's European distributors were selected based on prior experience in the point-of-care medical device and equipment sector, as well as knowledge with cardiac and central nervous system diseases. Each partner will be responsible for the distribution and marketing of SynX's point-of-care tests and research oriented products for congestive heart failure (CHF) and myocardial infarction. Expected to be commercially available in 2005, the CHF diagnostic product will measure NT-proBNP (N-terminal pro-hormone brain natriuretic peptide), a sensitive and specific biomarker for the diagnosis of congestive heart failure.

"These new distribution partners complement our existing distributor networks and provide us with significant relationships with point-of-care diagnostic decision makers in the hospital and research market segments," said Howard C. Birndorf, Nanogen's chairman of the board and chief executive officer. "Development of our congestive heart failure test is progressing and expansion of our distribution network is a key objective that will be important to the success of the product."

The newly expanded network provides SynX with exposure to a potential customer base of over 7,500 hospitals, 4,000 clinical laboratories and almost 11,000 cardiac specialists as measured by the European Diagnostic Manufacturers Association, excluding the newly emerging EU nations.

About Nanogen, Inc.

Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com.


SOURCE Nanogen, Inc.

CONTACT: Robert Saltmarsh, Chief Financial Officer of Nanogen, Inc., +1-
858-410-4600; or Pam Lord of Atkins + Associates, Media & Investor Relations,
+1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com/


This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission